The Use Of Nicotinic Acid In The Treatment Of Heart Disease

The Use Of Nicotinic Acid In The Treatment Of Heart Disease.
Combining the vitamin niacin with a cholesterol-lowering statin narcotic appears to provide patients no sake and may also increase side effects, a new study indicates. It's a sad result from the largest-ever study of niacin for heart patients, which involved almost 26000 people canadian accutane. In the study, patients who added the B-vitamin to the statin medicine Zocor saw no added promote in terms of reductions in heart-related death, non-fatal heart attack, stroke, or the need for angioplasty or ignore surgeries.

The study also found that people taking niacin had more incidents of bleeding and (or) infections than those who were prepossessing an inactive placebo, according to a team reporting Saturday at the annual meeting of the American College of Cardiology, in San Francisco. "We are disenchanted that these results did not show benefits for our patients," study clue author Jane Armitage, a professor at the University of Oxford in England, said in a meeting hearsay release tarika. "Niacin has been used for many years in the belief that it would help patients and prevent heart attacks and stroke, but we now remember that its adverse side effects outweigh the benefits when used with current treatments".

Niacin has covet been used to boost levels of "good" HDL cholesterol and decrease levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in kinfolk at risk for heart disease and stroke. However, niacin also causes a troop of side effects, including flushing of the skin. A upper called laropiprant can reduce the incidence of flushing in people taking niacin. This creative study included patients with narrowing of the arteries.

They received either 2 grams of extended-release niacin with 40 milligrams of laropiprant or matching placebos. All of the patients also took Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an general of almost four years.

Besides showing no profitable effect on heart health outcomes, the team noted that kin taking niacin had about the same amount of heart-related events (13,2 percent) as those who took a placebo a substitute (13,7 percent). Side effects were common. As already reported online Feb 26, 2013 in the European Heart Journal, by the end of the study, 25 percent of patients irresistible niacin and laropiprant had stopped their treatment, compared with 17 percent of the patients taking a placebo.